Tumour Board: CV Toxicity

In this week’s broadcast, presenters Dr Andrea Gallardo (University Hospital of Santiago de Compostela, ES), Dr Soledad Cincunegui (Institute of Oncology Angel H. Roffo, AR) and Dr Marcela Vinhola Grandini (Santa Casa de São Paulo, BR) are joined by a panellist of experts to review and discuss cancer cases, share expertise and collaboratively determine the most appropriate treatment plans for patients.

They will evaluate the potential benefits of treatment plans against the risks of cardiovascular toxicity, aiming to optimise cancer care while minimising harm to the patient's cardiovascular health.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.